Long-term efficacy of captopril in renovascular and essential hypertension
Authors:
- David B. CaseDCDavid B. Case
- Steven A. AtlasSASteven A. Atlas
- Rose Merie MarionRMRose Merie Marion
- John H. LaraghJLJohn H. Laragh
- 1 April 1982
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 49 (6) , 1440-1446
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Endocrine and Cardiovascular Influences of Converting Enzyme Inhibition with SQ 14225 in Hypertensive Patients in the Supine Position and during Head-Up Tilt before and after Sodium Depletion*The Journal of Clinical Endocrinology & Metabolism, 1980
- Haemodynamic Effects of Captopril in Hypertensive Patients: Comparison with SaralasinClinical Science, 1979
- Captopril in Hypertension with Renal Artery Stenosis and in Intractable Hypertension; Acute and Chronic Changes in Circulating Concentrations of Renin, Angiotensins I and II and Aldosterone, and in Body CompositionClinical Science, 1979
- Hormonal Changes with Long-Term Converting-Enzyme Inhibition by Captopril in Essential HypertensionClinical Science, 1979
- Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.Hypertension, 1979
- Converting enzyme inhibition with an orally active compound in hypertensive man.Hypertension, 1979
- Effects of angiotensin I-converting enzyme inhibitor, SQ 14225, in nomal men.Endocrinologia Japonica, 1979
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MANThe Lancet, 1977
- Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular diseaseThe American Journal of Medicine, 1972